The tweet was deleted by the author.
But we saved everything 🙂.
In a recent tweet, Patrick Soon-Shiong discusses a potential breakthrough in prostate cancer treatment.
The renowned entrepreneur and philanthropist emphasized the possibility of combining 'Anktiva' with 'Pluvicto' to create promising data in the fight against prostate cancer. Soon-Shiong, who has been at the forefront of innovative healthcare solutions, urged interested parties to engage with the clinic at CSSIFM for collaboration. 'Raising your NK and T cells can change the course,' he stated, hinting at the immunotherapy's potential to revolutionize patient outcomes.
However, Soon-Shiong noted the regulatory hurdles, explaining that applications to the FDA need to be submitted on a per-patient basis. He expressed confidence that these steps will be accomplished, signaling a proactive stance towards advancing cancer treatment modalities.
Soon-Shiong’s latest statements build upon his longstanding focus on advancing oncology therapies, reminiscent of the reported trial success for Abraxane in cancer treatment and its implications for patient survival. His broader perspective on cancer risks, including findings around the link between COVID-19 and increased throat cancer risk, underscores a continued commitment to innovative approaches in addressing complex health challenges.